Financials
Capital Efficient Growth
$18.5M
Total Raised
24 mo
Cash Runway
$25M
Series A Target
Series A Allocation
$25M raise — planned deployment
$25M
Series A
Clinical Ops
Phase I/II trials
$10M
40%
GMP Mfg
CDMO scale-up
$6.25M
25%
R&D
NHP & capsid dev
$5M
20%
G&A
Ops & working cap
$3.75M
15%
Cash Position & Runway
$M remaining — post-Series A close
Runway extends to Q1 2028 post-close. Series B trigger: Phase I/II interim data.
Funding History
Founder Round
$500K
2021
Pre-Seed — BioVenture
$3M
2022
Seed — Atlas, ARCH
$8M
2023
Seed Ext — OrbiMed
$7M
2024
Total Raised$18.5M